ImageneBio (IMA) vs Kalaris Therapeutics (KLRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImageneBio (IMA) has outperformed Kalaris Therapeutics (KLRS) over the past year, losing 44.7% versus a loss of 66.8%. Over five years, IMA leads with a -96.8% price change compared with -99.5% for KLRS. Kalaris Therapeutics is the larger company by market cap ($59.0 million vs $47.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMA | KLRS |
|---|---|---|
| Share price | $4.17 | $2.48 |
| Market cap | $47.43M | $59.04M |
| 1-day change | -9.54% | -3.12% |
| YTD return | -33.19% | -69.67% |
| 1-year return | -44.72% | -66.84% |
| 5-year return | -96.83% | -99.50% |
| EPS (TTM) | $-4.09 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.10 | $11.88 |
| 52-week low | $3.94 | $2.35 |
| Distance from 52-week high | -54.18% | -79.12% |
| Average volume | 12.81K | 251.42K |
| Shares outstanding | 11.37M | 23.80M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMA has outperformed KLRS by 22.1 percentage points over the past year.
IMA vs KLRS FAQ
Which is bigger, ImageneBio or Kalaris Therapeutics?
Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $59.04M compared with $47.43M for ImageneBio (IMA).
Which stock has performed better over the past year, IMA or KLRS?
IMA returned -44.72% over the past 12 months, compared with -66.84% for KLRS (price return, excluding dividends). Past performance does not predict future results.
Are ImageneBio and Kalaris Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.